Investigational drug · Phase 2
JAB-8263
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rheumatoid Arthritis (RA), NSCLC, SCLC.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "JAB-8263"
First trial start
2021
May 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JAB-8263", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis (RA)
- NSCLC
- SCLC
- CRPC
- ESCC
- Ovarian Carcinoma
- AML
- MF
- Malignant Tumor
Approved drugs for the same conditions: Non-small cell lung cancer · Rheumatoid arthritis · Oncology · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "JAB-8263" as an intervention, largest first.
Jacobio Pharmaceuticals Co., Ltd.Industry
NCT04686682 · 152 participants (planned) · Start May 7, 2021 · Primary completion Jan 2028
Drug: JAB-8263; JAB-8263 · For: NSCLC; SCLC; CRPC and 5 more
Sites: Tianjin, China
Jacobio Pharmaceuticals Co., Ltd.Industry
NCT04587479 · 41 participants · Start Nov 23, 2020 · Primary completion Oct 31, 2024
Drug: JAB-8263 · For: Solid Tumors, Adult
Sites: Denver, Colorado; Lake City, Florida; Nashville, Tennessee
Jacobio Pharmaceuticals Co., Ltd.Industry
NCT07684157 · 32 participants (planned) · Start Jul 23, 2026 · Primary completion Jun 30, 2027
Drug: JAB-8263; JAB-8263 · For: Rheumatoid Arthritis (RA)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties.
Yang G, Lin Y, Sun X, et al. · ACS Omega 2024
- Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models.
Liu XM, Xia SY, Long W, et al. · World J Gastrointest Oncol 2023
Also in development for Rheumatoid Arthritis (RA)
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
Beijing VDJBio Co., LTD. · Anti IL-6R, Idiopathic Multicentric Castleman's Disease, Castleman's Disease, Multicentric
- proposed biosimilar to etanerceptMB04Phase 31 trial
mAbxience Research S.L. · Rheumatoid Arthritis (RA)
- AP1189Phase 23 trials
SynAct Pharma Aps · Rheumatoid Arthritis (RA), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy
- QLS12010Phase 23 trials
Qilu Pharmaceutical Co., Ltd. · Adults With Moderate-to-severe Hidradenitis Suppurativa, Moderate-to-severe Atopic Dermatitis, Rheumatoid Arthritis (RA)
- TollB-001Phase 22 trials
Toll Biotech Co. Ltd. (Beijing) · Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
- FT839Phase 21 trial
Fate Therapeutics · ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA)
- QEL-005Phase 21 trial
Quell Therapeutics Limited · Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.